Of Integrity, Persistence, Leadership, and Responsibility: Mount Sinai Graduate Students Start Their Science Training

Alec C. Kimmelman, MD, PhD, keynote speaker at Mount Sinai’s Lab Coat ceremony

Alec C. Kimmelman, MD, PhD, stepped to the podium as the keynote speaker at Mount Sinai’s Lab Coat Ceremony, the celebratory start of academic research and training for the newest PhD and MD-PhD students. He recalled how he had felt a few decades earlier when he was a Mount Sinai student. “I remember sitting in the same place,” he said, “and I was wondering what the future would hold.”

For Dr. Kimmelman, who received both his MD and PhD degrees at Mount Sinai in 2003, it would be a future of extraordinary successes—starting with his own research thesis, which set the theme for his career investigating RAS-gene-driven cancers. As a student, he would also identify and characterize a novel member of the RAS family of oncogenes, and publish three first-author papers on this topic. Today, Dr Kimmelman, one of the world’s foremost authorities on the biology of pancreatic cancers, is the newly named Dean of the NYU Grossman School of Medicine and Chief Executive Officer of NYU Langone Health.

“New tools like artificial intelligence may change the scale of discovery but they don’t change its heart,” Dr. Kimmelman told the students. “At its core, science is built on people, and the way we choose to lead each other. When I was a trainee, I didn’t think of myself as a leader in any formal sense. Leadership seems like something reserved for deans or department chairs, but I soon learned that leadership often begins in the lab.” It is where building trust and “other small acts—mentoring, collaborating, encouraging—taught me that leadership is less about hierarchy and more about responsibility,” he said.

Celebrating PhD and MD-PhD students after getting their lab coats.

“Years later, when I was asked to lead a lab, and then a cancer center and, now, a health system, the principles were the same: create an environment where curiosity can thrive, where people support one another, and where integrity is never compromised. The qualities you demonstrate every day at the bench—generosity, persistence, intellectual courage—may one day prepare you for opportunities you cannot yet imagine. Leadership is not something that you wait for a title to give you. It’s something you practice, here and now, in how you approach your science and your colleagues.”

Marta Filizola, PhD, Dean of the Graduate School of Biomedical Sciences at the Icahn School of Medicine at Mount Sinai, presided over the ceremony, which was held Thursday, September 4, at Goldwurm Auditorium.

“At Mount Sinai, we continue to advance into frontiers of research that integrate cutting-edge approaches across disciplines, from artificial intelligence and data science, to stem cell biology and regenerative medicine, all aimed at improving human health and quality of life,” she said. “Our students are at the heart of this work, bringing diverse perspectives, creativity, and a relentless drive to push the boundaries of both basic and translational research.” Dr. Filizola is also the Sharon & Frederick A. Klingenstein/Nathan G. Kase, MD Professor of Pharmacological Sciences, Professor of Neuroscience, and Professor of Artificial Intelligence and Human Health.

From left: Sarah E. Millar, PhD, Dean for Academic and Scientific Affairs, Icahn School of Medicine at Mount Sinai; Eric J. Nestler, MD, PhD; Alec C. Kimmelman, MD, PhD; and Marta Filizola, PhD, lead the students in reciting the Oath for Doctoral Students.

Eric J. Nestler, MD, PhD, Interim Dean and Nash Family Professor of Neuroscience at the Icahn School of Medicine at Mount Sinai, and Executive Vice President and Chief Scientific Officer of the Mount Sinai Health System, welcomed the students and guests and spoke about the vast advances in health care made possible by science, today’s challenges to scientific inquiry, and, significantly, the need for optimism and new discoveries.

“Advances now occurring in the laboratory and clinic, driven in part by the power of computational and molecular biology and artificial intelligence, and informed by unprecedented volumes of biomedical data,” Dr. Nestler said, “will fundamentally transform the way we understand, diagnose, treat, and prevent disease. We must shout this from the mountaintops.”

However, “We live in a time when some people do question the value of scientific inquiry,” he added. “Efforts to politicize science are most unfortunate. Today, we are seeing an unprecedented assault on the nation’s scientific enterprise.”

Still, “We must remain optimistic,” he urged. “The importance of biomedical research is too strong and too widely held for us to back away, and the biomedical research enterprise is more exciting and promising today than ever before in world history.”

 

Click on the arrows below for a slideshow of faculty and students.

A New Era in Rehabilitation at Mount Sinai: Advanced Center Opens at Mount Sinai Morningside

Mount Sinai Health System has opened the newly relocated Mount Sinai Rehabilitation Center at Mount Sinai Morningside, marking a major milestone in rehabilitation medicine. The move expands inpatient rehabilitation capacity on Manhattan’s West Side—complementing Mount Sinai West—and establishes a state-of-the-art environment for patient care, research, and education.

“We’re already a magnet for patients from across the country and the world,” says Joseph Herrera, DO, Chair of Rehabilitation Medicine and Human Performance for the Mount Sinai Health System. “Now, our patients will receive care in a setting designed specifically for rehabilitation.”

Joseph Herrera, DO

State-of-the-Art Facilities

The redesigned unit is centered on patient recovery, safety, and accessibility, offering services for those recovering from spinal cord and brain injuries, stroke, and other neurological conditions.

Each large room is equipped with ceiling lifts to support mobility, while also accommodating power wheelchairs and robotic exoskeletons used in therapy.  Rooms feature digital technology that enhances accessibility, communication, and the overall patient experience.  There are several large gyms and therapy spaces, outfitted with the latest rehabilitation equipment to maximize patient recovery.

“This renovation allows us to move forward in both patient care and innovation,” says Dr. Herrera. “We now have the capacity to test and refine technologies that may become tomorrow’s standard treatments.”

A Hub for Research and Innovation

The new facility also provides expanded space for clinical research, allowing teams to pilot cutting-edge rehabilitation technologies such as robotic mobility aids, exoskeletal walking therapy, and immersive virtual reality platforms.

“These advances aim to improve recovery outcomes and restore independence for patients with complex conditions,” says Dr. Herrera.

Nationally Recognized Programs

Mount Sinai Rehabilitation Center has earned national recognition as one of only 15 National Innovation Rehabilitation Centers in the United States, under the Dr. Joanne Smith Memorial Rehabilitation Centers Act of 2023. It also serves as a nationally designated Spinal Cord Injury Model System and Traumatic Brain Injury Model System, with federal funding from the National Institute on Disability, Independent Living, and Rehabilitation Research.

The Center is accredited by the Commission on Accreditation of Rehabilitation Facilities (CARF) for seven inpatient programs in spinal cord injury, brain injury, stroke, and comprehensive inpatient rehabilitation.

“With its expanded facilities, nationally recognized expertise, and cutting-edge therapies, the new Mount Sinai Rehabilitation Center at Mount Sinai Morningside marks a new era in helping patients achieve recovery, independence, and hope,” says Dr. Herrera.

Click here to learn more

Comprehensive, Specialized Care

The center’s multidisciplinary teams include physicians, nurses, therapists, neuropsychologists, and social workers, ensuring individualized care for patients. Specialized programs include:

  • Spinal Cord Injury Rehabilitation – The only CARF-accredited program of its kind in New York City, offering robotic exoskeletons, mobility aids, and advanced therapy tools.
  • Brain Injury Rehabilitation – Integrated physical, cognitive, and psychological therapies with seamless outpatient follow-up.
  • Stroke Rehabilitation – High-intensity, interdisciplinary therapy complemented by peer support.
  • Amputation and Prosthetics Program – Pre- and post-prosthetic training, plus mentoring from peers with lived experience.
  • Exoskeletal Walking Therapy – Powered mobility support for patients with neurological conditions.
  • Neurologic Rehabilitation – Personalized care for conditions such as Parkinson’s disease, multiple sclerosis, and brain tumors.

How Mount Sinai Queens Saved a Colleague’s Life

Frank Parlatorre, center, Environmental Services, with a team of his colleagues who saved his life. From left: Mark Dela Cruz-Hunt, RN, RN, MHL, Clinical Nurse Manager; Francis Cortes, RN, BSN; Juliana Mariano, RN; Charmaine Escutin, RN; Jonathan Luke Murphy, MD; George Dangas, MD, PhD, Director, Cardiology; Kamran Babri, BLS, ACLS, RCIS, Cath Lab Lead Cardiovascular Tech; Anshika Rani, Physician Assistant; Michelle Hang, AGACNP-BC; Gian Florendo, Senior Physicians Associate; Sharri Keveson, RN; and Stefanie Pinto, RN

It started like any other day—until it wasn’t. On the morning of Thursday, February 20,  Frank Parlatore, Jr., a member of the Environmental Services team at Mount Sinai Queens, was preparing for his shift when he collapsed in the operating room locker room.

Frank had gone into sudden cardiac arrest, and his colleagues and friends, including nurses in the Post-Anesthesia Care Unit (PACU) and operating room, sprang into action and performed CPR right then and there. What happened next was a powerful reminder that at Mount Sinai, the commitment to care doesn’t stop with patients. Staff in the Mount Sinai community take care of each other, too.

“He had a cardiac arrest caused by severe coronary artery disease,” explains Georgios Syros, MD, Director of Cardiac Electrophysiology at Mount Sinai Queens. “He had multiple blockages—three-vessel coronary artery disease—and a weak heart, with only about one-third of normal function.” Lifestyle factors, including smoking and not seeing a doctor regularly, had contributed to his condition.

Following his initial stabilization, Frank was taken to the Emergency Department (ED), where the ED and ICU physicians performed resuscitation efforts for almost 40 minutes. After a normal rhythm was restored, he was taken for a coronary angiogram at the recently opened Mount Sinai Queens Cardiac Catheterization Laboratory. The angiogram confirmed the extent of his coronary blockages. Frank’s heart stopped again in the Cath Lab.  He was revived by Jonathan L. Murphy, MD, who used CPR and multiple defibrillation treatments.

Frank was placed on a respirator and fitted with a specialized device to support his circulation. Then, he was transferred to The Mount Sinai Hospital, where his heart function partially improved with medical therapy under the guidance of Ahmed El-Eshmawi, MD. In March 2025, Dr. Syros performed an electrophysiology study and implanted a defibrillator at Mount Sinai Morningside to help prevent life-threatening arrhythmias.

Over the next several weeks, Frank’s heart function continued to improve. By May, he was strong enough to undergo a double-vessel coronary artery bypass. The surgery was a success, and just months after that harrowing February morning, Frank was recovering exceptionally well.

“It’s not every day that the person on your OR table is also someone you know and work with,” Dr. Syros says. “That made it even more personal to me and the entire team to do everything we could to bring him back. This was Mount Sinai Queens at its best—quick thinking, teamwork, and compassion.”

How a Passion for Pharmacology and Addressing Substance Use Disorders Brought an Aspiring Researcher to Mount Sinai

Ally Parpounas, MS

Ally Parpounas, MS, is a second-year student in the MD program at the Icahn School of Medicine at Mount Sinai. She previously completed the Master of Science in Biomedical Science (MSBS) at the Graduate School of Biomedical Sciences.

It was her decision to attend the MSBS program at Mount Sinai, along with her eventual participation in a number of different programs sparked by her desire to help people in need, that would lead to medical school, which in turn has opened a number of different career pathways.

Ms. Parpounas studied neuroscience at George Washington University in Washington, D.C. and studied abroad at the Danish Institute of Study in Copenhagen, Denmark. While at the Institute, she took a psychopharmacology course that sparked her interest in research. The course taught students how neural circuitry is implicated in various psychiatric conditions. She learned how to redirect it by developing a “pharmacological cocktail” that would minimize both side effects and symptoms.

“This experience unlocked my curiosity about the physiologic mechanisms that underlie disease, and so I  began to consider a career in medicine,” she says. She soon changed her major from psychology to neuroscience.

After completing her undergraduate program in 2020, she took a gap year working at an in-patient acute care psychiatric hospital in Washington D.C. She worked there for a year before deciding that she needed more basic research experience before medical school. A Master of Science in Biomedical Science seemed like a natural next step.

While looking at master’s programs, she noticed Mount Sinai’s MSBS program. She began looking into a few labs to determine what she wanted to study and focus on. She was drawn to the pharmacology research of the Daniel Wacker, PhD lab, where she would eventually be placed. She applied to a few other programs, but the MSBS program at Mount Sinai stood out because of the strong research component. She was also interested in living in New York City because it was close to where she grew up in Peekskill, New York, about an hour north of the city. She started the MSBS program in August 2021.

During her time in the program, she worked in a number of different areas that would eventually help shape her interest in a future career in medicine.

She volunteered and conducted clinical shadowing with the Mount Sinai Human Rights Program, which provides medical and psychological evaluations for people seeking asylum in the United States. The program helps people who are typically victims of human trafficking, political violence, and other difficult circumstances. They use these evaluations and affidavits to assist with asylum cases. She worked as one of the lead clinic managers.

“The program has shown me how we can leverage our roles as clinicians to protect the health and human rights of individuals, in addition to the traditional role providing direct medical care,” she says. “It’s incredible to see the impact you make on someone life beyond just their medical care.”

She also led the graduate school’s mentorship program. Mentors help first year students navigate decisions, such as determining what they want in a lab placement. Her positive experience doing this in her first year inspired her to act as a mentor for other students during her second year.

She was also a clinic manager at the East Harlem Outreach Partnership (EHHOP), the Icahn School of Medicine’s student-run, physician-supervised, free clinic. She has continued this work while in medical school as a part of the Access to Care Team, which helps patients gain access to medicines, healthy food, and legal assistance. She  is now on ACT team leadership as the ACT Resources Chair.

She believes that the opportunities she had to get clinical experience helped shape her drive towards medical school.

“My previous experiences helped inform my direction for medical school and the type of work I want to do when I become a physician,” she says. “My training in the MSBS program helped make me a more thoughtful and intentional applicant to medical school.”

“The program has shown me how we can leverage our roles as clinicians to protect the health and human rights of individuals, in addition to the traditional role providing direct medical care. It’s incredible to see the impact you make on someone life beyond just their medical care.”

The Graduate School provides support to help master’s students seeking to continue their education through PhD or MD programs. Ms. Parpounas  worked with a student advisor in the Medical Scientist Training Program (MSTP) that helped with her medical school application process. The student advisors provide services such as creating an MCAT study schedule and essay review and revision help. This support was available as needed, but it was up to Ally to schedule meetings and manage the process.

“When I was studying for the MCAT exam, my friends in the medical school and the MSAP advisors (the MSTP student advisors) recommended study plans and resources, like Anki flashcards, that were more similar to what people use in medical school vs undergrad. I think studying in this way helped me get an MCAT score that I was proud of and made me feel more ready for the academic rigor of medical school,” she says.

She completed the MSBS program in June 2023 and received the Award for Excellence in Biomedical Science Leadership and Service Award for her volunteering and mentorship. She then applied to a few MD programs and was accepted to the program at the Icahn School of Medicine. Ally appreciates being in the first class to experience the new ASCEND curriculum, which was introduced in the fall of 2024. The objective of this curriculum revamp is to provide a personalized and active-learning approach aimed at transforming the way knowledge and clinical experiences are acquired.

Upon completing her MD, Ally is interested in a few different paths in medicine. She is currently working with Leah Habersham, MD, Director of the Bridge Program at Mount Sinai. The Bridge Program is an integrated clinic providing women’s health care, including obstetrics and gynecology, along with care for substance use disorder.

These experiences at Mount Sinai have sparked an interest in a wide variety of areas, including specialties such as obstetrics and gynecology, pediatrics, and internal medicine. But she believes it’s important to keep an open mind and will explore more once she begins her clinical clerkships in February 2026.

Stories Behind the Science: Preparing to Fight the Next Epidemic

Stories Behind the Science: Preparing to Fight the Next Epidemic

Kris White, PhD, Assistant Professor of Microbiology at the Icahn School of Medicine at Mount Sinai (right), and lab member Isidora Suazo, PhD, Postdoctoral Fellow (left), are part of a research network to discover new drugs for a viral epidemic preparedness initiative.

It was June 2022, and Peter White, a lawyer from Point Lookout, Long Island, was in Florida attending a work event. As he was waiting for his flight home, he started to feel sick.

“By the time I landed, I was very sick with a heavy pressure in my chest,” said Mr. White, 67. “Any time I had previously felt like this, it had always, at a minimum, developed into bronchitis or pneumonia.”

Mr. White was worried it was COVID-19, which could spell poor outcomes given his underlying respiratory condition. “When I get a cold, it has a tendency to morph into bronchitis and, at times, pneumonia. I’ve had walking pneumonia several times, as well as regular pneumonia,” he said. “I can’t count the number of times I have had bronchitis.”

His doctor advised him to go to the emergency room to seek treatment for COVID-19. Thankfully, just months prior—in December 2021—the antiviral medication Paxlovid (nirmatrelvir/ritonavir) from Pfizer had become available via emergency use authorization for the treatment of COVID-19.

“I did not feel better right away,” Mr. White recalled. “However, I did not get worse, which was huge given my prior history, and it was a comfort for me that the drug was working.”

“Thankfully, his bout with COVID-19 ended up being uneventful, because he was able to take Paxlovid quickly and clear it out of his system,” said Kris White, PhD, Assistant Professor of Microbiology at the Icahn School of Medicine at Mount Sinai and Mr. White’s son.

“The COVID-19 pandemic really taught us the value of having treatments ready to test and deploy quickly when an epidemic hits,” said Dr. White.

Mount Sinai has been working toward that goal, in part through its involvement in the Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern, established in 2022 by the National Institutes of Health (NIH). Dr. White’s lab is among several at Mount Sinai contributing research as part of the AViDD Centers, developing antiviral drugs to tackle future outbreaks.

Dr. White (second from right) with his father, Peter (second from left), with five of Dr. White’s children and two nieces. Peter caught COVID-19 in 2022, but with Paxlovid antiviral treatment, it did not develop into something severe, for which Mr. White was at high risk.

However, recent cuts to NIH funding have threatened to stall progress. “We were halfway to the finishing point,” said Dr. White. “With our funding cut, it is like we have half a drug—and that is of no good to anyone.”

Read about how antiviral research can help us navigate future epidemics, and challenges the AViDD Centers face.

‘It Could Have
Been A Very
Different Pandemic’

The issue with relying solely on pharmaceutical companies to develop drugs for an epidemic is that until the health crisis is at hand, there is no incentive for them to carry out such research, noted Dr. White.

That was the case with COVID-19—when it hit in early 2020, there were few if any drug candidates to test right away. Pharmaceutical companies and academic institutions scrambled to find new compounds, or repurpose old ones, that could treat the infection.

Pfizer had a lead, PF-07321332, which had potential for targeting SARS-CoV-2, the virus that causes COVID-19. It was developed in 2003 to address the severe acute respiratory syndrome (SARS) outbreak in 2002-2004. But before it could make it into human clinical trials, the outbreak was contained and development was discontinued.

Even promising compounds take time before they can be used on patients. It wasn’t until March 2021 that Pfizer announced it would test PF-07321332 in humans in a phase 1 trial. In June that year, a phase 2/3 trial was carried out to test its effectiveness, and in December, the compound, which had been named Paxlovid, received its emergency-use authorization.

“We’ve seen that given the will, we can quickly test the effectiveness and safety of treatments and make them available to the public,” said Dr. White. “Imagine if we had compounds ready to test right at the beginning, it could have been a very different pandemic.”

For Dr. White’s father, that difference was between life and death. “Paxlovid was a game changer for me,” said Mr. White. “Knowing that I was most likely going to suffer, but not die, from COVID-19 was good news. It would have been better if this drug was available sooner rather than later.”

Having treatments available early on not only reduces transmission, disease severity, and mortality rates, but also has an impact on health policy.

“Having such an antiviral could even have mitigated the need for severe lockdowns, or even vaccine mandates,” said Dr. White. For people who might be ineligible for vaccines, or were resistant to such mandates, having a treatment available would have provided options for health providers and policymakers, he explained.

March 2020

The World Health Organization declares COVID-19 a pandemic.
September 2020

Pfizer completes pharmacokinetic study of PF-07321332 in rats.
March 2021

PF-07321332 tested in a first-in-human phase 1 trial.
June 2021

Phase 2/3 trial for PF-07321332 begins.
December 2021

PF-07321332 receives emergency-use authorization from the FDA, is named Paxlovid.

Kickstarting the Process

Dr. White, seen dressed in protective clothing, works with Biosafety Level 2 and Biosafety Level 3 viruses as part of his work. His lab’s research includes drug discovery of new antivirals and building up animal models of viral infection.

Following the authorization of Paxlovid, the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, realized the benefits of having promising drug candidates ready to be tested at the onset of an outbreak.

“Academic institutions like Mount Sinai were perfectly suited for kickstarting that discovery work,” said Dr. White, whose lab studies viral-host interactions, develops cell culture and animal models of viral infection, and performs other antiviral drug discovery work.

Members of Dr. White’s lab, from left to right: Briana McGovern, BS, Senior Research Associate; Meg Gordon, BA, Research Associate; Dr. White; Dr. Suazo; Jared Benjamin, MS, Research Associate.

“Historically, drug discovery was a process that took billions of dollars, and was usually undertaken by pharmaceutical companies,” said Dr. White. “Now, with technological advances and artificial intelligence, the cost of that process has been brought down to millions of dollars, which is a realm that the federal government can provide funding for.”

NIAID awarded a total of $577 million in 2022 toward the creation of nine AViDD Centers, which collectively work to discover better treatments for SARS-CoV-2 and other coronaviruses, as well as six other pathogen families of concern, which include Ebola, Zika, and other cold-causing viruses. Mount Sinai researchers received a total of $16 million and are involved in four of the nine centers.

Progress
Cut Short

Dr. White handling cell cultures stored in a cold storage unit in his lab.

The AViDD Centers were conceived as a five-year project. However, in March 2025—three years into the Centers’ inception—the Centers for Disease Control and Prevention canceled more than $11 billion in funding earmarked for pandemic response.

This included funding for the AViDD Centers, where researchers had the remainder of their unspent budget terminated immediately, pulling out the rug from under several projects.

“I’ve had to let people go from my lab, and we’re currently working in an unfunded state for the AViDD project,” said Dr. White. “We’re only continuing because we had prepaid for certain things before the funding cutoff.”

The most advanced drug developed thus far was basically a better Paxlovid for targeting coronaviruses, but without the need for the ritonavir component, said Dr. White. This is critical because the ritonavir component severely limits the use of Paxlovid in some patients due to drug interactions with other drugs. That compound is more or less ready for a pharmaceutical company to take over for clinical trial testing, with its patents remaining open access, as directed by the NIH.

“We have an excellent coronavirus drug ready to go to clinical trials, but every other drug for the other viruses—paramyxovirus, filovirus, flavivirus, and more—none of them are even close,” he said.

At best, work on the other viruses are close to getting their animal model efficacy data, which is crucial for moving the drugs into human models, said Dr. White. “Getting animal model data is hard enough in five years. Without funding for the remaining two years, getting that data in just three years is almost impossible.”

The drug dispensing robotics system, operated by research associate Mr. Benjamin in this photo, is part of the workflow in which the lab tests new antiviral compounds, said Dr. White. The equipment functions similar to an inkjet printer, and is able to print drugs into a plate format.
Dr. White’s lab had been working on animal models of coronaviruses, flaviviruses, and enteroviruses, and with funding for AViDD Centers abrupted halted, cultures remain in cold storage, waiting for work to resume.
Mr. Benjamin is monitoring the high throughput liquid handler system, which increases the number of samples that can be tested. Throughput is what drives drug discovery, and the lab was able install the equipment thanks to AViDD Centers funding, said Dr. White.

Operating costs for AViDD projects are on a larger scale because they involve high-throughput structural biology and biochemistry that run millions of dollars per year, noted Dr. White. Researchers are reaching out for patchwork funding to keep operations going, including from the Department of Defense, NIH, not-for-profit organizations such as the Drugs for Neglected Diseases initiative, and philanthropy.

Getting continued funding is crucial because viral outbreaks do not take breaks.

“At our labs, we’ve been focusing on Zika virus disease and dengue fever, and these are viral infections we’ve already seen on our shores but still have no treatments for,” said Dr. White.

“At the end of the day, I want to be able to keep my dad and many other people like him safe when—and not if—the next viral outbreak occurs,” said Dr. White. “We were already caught by surprise once with COVID-19. Let’s not have history repeat itself again.”

Advancing Our Understanding of MS: One Researcher’s Quest to Uncover Hidden Brain Changes

Caption: An image from a standard clinical MRI, left, compared with an image from the same person using advanced methods on a stronger, 7T MRI. Compared to the standard clinical MRI, the research MRI is much clearer and multiple sclerosis lesions (dark spots) are more clearly seen.

How can clinicians better predict who will transition from relapsing to progressive Multiple Sclerosis (MS)? And can we use imaging techniques to diagnose MS more accurately and to select the right treatments for individual patients?

“These are questions people with MS and their doctors struggle with frequently, and so we hope to at least begin to answer them through our research,” says Erin S. Beck, MD, PhD, Assistant Professor of Neurology at the Icahn School of Medicine at Mount Sinai and a neurologist at the Corinne Goldsmith Dickinson Center for Multiple Sclerosis.

Erin S. Beck, MD, PhD

Dr. Beck, whose research program explores the intersection of neuroimaging, immunology, and clinical  care, is seeking answers using advanced magnetic resonance imaging (MRI).

“At the heart of our work is a commitment to advancing both science and patient care,” says Dr. Beck. “By deepening our understanding of cortical lesions and the inflammatory processes that drive them, we are helping to shape a more precise and informed future for MS diagnosis, treatment, and care.”

For MS patients, the implications of this work are significant. If these imaging methods are validated, cortical lesion detection could become part of routine MRI protocols within the next several years. This could enable earlier and more accurate diagnosis, improve predictions of how a patient’s disease will unfold, and support more personalized treatment decisions.

Dr. Beck’s lab studies how lesions in the brain and spinal cord form, evolve, and repair in MS and other related diseases. A central focus of her lab’s research is understanding MS lesions in the cortex, the outer layer of the brain, which helps to control most of the brain’s functions. While white matter lesions are well-established markers of MS activity, they explain only part of the disease.

Cortical lesions, though harder to detect with standard imaging, are increasingly recognized as widespread in MS and closely tied to physical disability and cognitive impairment, particularly in progressive forms of the disease. It is unclear whether current MS treatments, which work by stopping new lesions from forming in the rest of the brain, are also effective at stopping cortical lesion formation.

Using state-of-the-art imaging technologies—including more powerful, 7 tesla (T) MRI scanners—Dr. Beck combines MRI with cerebrospinal fluid (CSF) and blood analysis to investigate the formation, repair, and clinical significance of cortical lesions. Her research integrates imaging with measures of inflammation, aiming to discover how immune processes contribute to lesion development and disease progression.

One of her lab’s key contributions is the development of MRI methods to improve cortical lesion detection using widely available 3T MRI scanners. These include IR-SWIET, a novel MRI method specifically optimized for visualizing cortical lesions. The lab is currently testing whether IR-SWIET could be useful for MS diagnosis and for monitoring response to treatment.

Her investigations also extend to patients with Radiologically Isolated Syndrome (RIS)—those whose MRI scans show MS-like lesions despite having no symptoms. Through advanced imaging and CSF studies, she hopes to identify biomarkers that distinguish individuals likely to develop clinical MS from those who will remain symptom-free.

Dr. Beck earned her MD/PhD from Columbia University. Following her neurology residency at New York–Presbyterian/Columbia and a neuroimmunology fellowship at the National Institutes of Health, she joined Mount Sinai’s faculty in 2021. Since then, she has been building her research program at the intersection of neuroimaging, immunology, and clinical MS care.

Dr. Beck’s research has been recognized with awards such as a Clinician Scientist Development Award and a Career Transition Fellowship from the National MS Society. Her findings have been published in leading journals, including Brain Communications, Investigative Radiology, and Human Brain Mapping.

By Julia Bonem, a volunteer at the Corinne Goldsmith Dickinson Center for Multiple Sclerosis

Pin It on Pinterest